Considering the diversity of the agents (Gram-positive and Gram-negative and intracellular and extracellular bacteria) and of the routes of infection tested (i.n., i.p. and i.v.), these results so far support the assumption that SIRT5 has no dramatic influence on host defenses against bacterial infections and the clinical development of SIRT5 inhibitors for oncologic purposes (18, 22). The gene discussed is SIRT5; the disease is infection.